Preclinical antiviral study of a liver-targeted TLR1/2 agonist in an immune-competent mouse model of HBV infection
Fanny Charriaud, Myriam Lamrayah, Romain Barnault, Svenja Schuehle, Manon Desmares, Mathias F Heikenwälder, Julie Lucifora, Bernard Verrier, David Durantel
This study evaluates a liver-targeted TLR1/2 agonist nanoparticle formulation for HBV treatment, showing enhanced antiviral effects compared to free agonist in mice.
bioRxiv · May 27, 2026 · PreprintMicrobiology